Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

No reported Net Debt figures are available to summarize.

Net Debt history

Currency unavailable · from the balance sheet

No Net Debt data reported for this period type.

Net Debt vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Net Debt for KARD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CYTKCytokinetics, IncorporatedJun 2026$1.02B USD+29.6%+19.3%52.8%
IKTInhibikase Therapeutics, Inc.Mar 2026-$49.57M USD+32.4%—28.6%
TNYATenaya Therapeutics, Inc.Mar 2026-$70.77M USD-73.2%—52.4%
RNAAtrium Therapeutics, Inc.Mar 2026-$265.17M USD——90.7%
NAMSNewAmsterdam Pharma Company N.V.Jun 2026-$424.07M USD+24.7%—60.2%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+27.2%+19.3%52.8%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.